Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans

PR Newswire December 7, 2020

RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19

PR Newswire November 25, 2020

RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences

PR Newswire November 23, 2020

RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease

PR Newswire November 20, 2020

RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib

PR Newswire November 19, 2020

RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease

PR Newswire November 17, 2020

RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks

PR Newswire November 16, 2020

RedHill Biopharma to Present at German Equity Forum 2020

GlobeNewswire November 13, 2020

RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth

GlobeNewswire November 12, 2020

RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020

GlobeNewswire November 5, 2020

RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination

GlobeNewswire November 4, 2020

RedHill Biopharma Presents New Data from Talicia®'s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication

GlobeNewswire October 26, 2020

RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections

GlobeNewswire October 14, 2020

RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib

GlobeNewswire October 13, 2020

RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca

GlobeNewswire October 8, 2020

RedHill Biopharma's Opaganib COVID-19 Study Passes Second Independent Committee Review

GlobeNewswire October 7, 2020

RedHill Biopharma to Present at BIO Investor and BIO-Europe 2020 Virtual Conferences

GlobeNewswire October 6, 2020

Brazil Approves RedHill Biopharma's Phase 2/3 COVID-19 Study with Opaganib

GlobeNewswire September 22, 2020

RedHill to Present at the Morgan Stanley Annual Global Healthcare Conference and Additional September Events

GlobeNewswire September 9, 2020

RedHill Biopharma's Opaganib Demonstrates Complete Inhibition of SARS-CoV-2

GlobeNewswire September 8, 2020